USPTO 2015–2025 USPTO PatentsView US Corporation

Edwards Lifesciences Corporation

USPTO PatentsView assignee record - 1,265 granted patents across 51 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Edwards ranks #340 of 49,997 tracked US assignees by granted-patent volume, with 1,265 patents across 51 technology areas.

#340
of 49,997 US assignees by volume
Top 1%
by Innovation Score (67.2/100)
18.6
avg claims per patent
+83%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R340 · US Corporation #340 · 1,265 grants

GRANTS-LARGE · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-LARGE 1.3K grants
  • TOP-DECILE #340/49,997
  • PHOTO-FINISH The Trustees of the…
  • CPC-WIDE A61F · 51 areas
  • INNOV-STRONG 67.2/100
  • CLAIMS-RICH 18.6 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +83% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: The Trustees of the University of Pennsylvania (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Edwards

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Edwards's Innovation Score is 67.2/100 (top 1% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Edwards's grant cadence moved

Between 2020–2024, Edwards Lifesciences Corporation received 732 grants versus 401 in 2015–2019 (+83% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2024 at 172 grants and bottomed in 2015 at 49. Lead class A61F accounts for 87% of the portfolio across 51 subclasses. Volume neighbours: Google Technology Holdings LLC (#336) and Merck Sharp & Dohme LLC (#344).

Edwards's three-year grant acceleration

From 2019–2021 to 2022–2024, Edwards Lifesciences Corporation moved from 444 to 422 grants (0.95x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,318. See the growth leaderboard.

Who files at Edwards's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Edwards holds 1,265 patents at rank #340, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Edwards

By rank, the assignees closest to #340 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Edwards's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Edwards, neither rank-band nor same-CPC leaders (those blocks stay above).

Edwards's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

67 Top 1% higher than 99% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

050100150200 20152016201720182019202020212022202320242025 132
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Edwards Lifesciences Corporation patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 49 3.9%
2016 66 5.2%
2017 61 4.8%
2018 91 7.2%
2019 134 10.6%
2020 153 12.1%
2021 157 12.4%
2022 112 8.9%
2023 138 10.9%
2024 172 13.6%
2025partial year 132 10.4%

Which technologies does Edwards Lifesciences Corporation patent most?

Top 15 of 51 technology areas

Where it ranks

Overall rank by patents

#340

of 49,997 tracked assignees

Innovation Score

67.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Edwards Lifesciences Corporation's patent record in context - here's where to go next.

  • Edwards Lifesciences Corporation's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 87% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #340 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Edwards Lifesciences Corporation against Google Technology Holdings LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 67.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.